Day: May 10, 2024

Paul Mueller Company Announces Expiration of Share Repurchase Program and Declares Quarterly Cash Dividend

SPRINGFIELD, Mo., May 10, 2024 (GLOBE NEWSWIRE) — Paul Mueller Company (OTC: MUEL) today announced that its Board of Directors has declared a cash dividend of 23 cents ($0.23) per share on its outstanding common stock. The action was taken on May 10, 2024, at a regular meeting of the Board of Directors. The dividend of 23 cents ($0.23) per share is payable on June 28, 2024, to shareholders of record on May 24, 2024. Additionally, on May 7, 2024, the tender offer announced on March 15, 2024, expired with 148,874 shares being tendered for a total of $11,909,920. On May 13, 2024, Computershare, the Depository for the tender offer, will deliver funds to the Depository Trust Company to be disbursed to the brokerage accounts of those who tendered shares. On May 14, 2024, Computershare will mail checks to those registered shareholders...

Continue reading

Tandy Leather Factory Reports First Quarter 2024 Results

FORT WORTH, Texas, May 10, 2024 (GLOBE NEWSWIRE) — Tandy Leather Factory, Inc. (Nasdaq: TLF) today announced the Company’s financial results for the first fiscal quarter of 2024. Highlights from First Quarter 2024: Revenues were $19.3 million, down 5.3% from 2023 Generated operating income of $0.7 million Net income of $0.5 million, down from $0.7 million in 2023 Gross margins of 56.7%, down from 58.1% in 2023 Operating expenses $10.3 million, down 5.2% from 2023 Adjusted EBITDA* of $1.1 million Ended quarter with $12.3 million of cash and cash equivalents Tandy Leather Factory’s first quarter sales were $19.3 million in 2024, down from $20.4 million in 2023. First quarter 2024 gross profit was $10.9 million, down from $11.8 million in 2023. First quarter operating income was $0.7 million, down from $1.0 million in 2023. As of...

Continue reading

CPS Announces First Quarter 2024 Earnings

Revenues of $91.7 million compared to $83.1 million in the prior year period Pretax income of $6.6 million Net income of $4.6 million, or $0.19 per diluted share New contract purchases of $346.3 million LAS VEGAS, NV, May 10, 2024 (GLOBE NEWSWIRE) — Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced earnings of $4.6 million, or $0.19 per diluted share, for its first quarter ended March 31, 2024. This compares to a net income of $13.8 million, or $0.54 per diluted share, in the first quarter of 2023. Revenues for the first quarter of 2024 were $91.7 million, an increase of $8.6 million, or 10.4%, compared to $83.1 million for the first quarter of 2023. Total operating expenses for the first quarter of 2024 were $85.2 million compared to $64.7 million for the 2023 period. Pretax income for...

Continue reading

Apollo Tactical Income Fund Inc. Declares May 2024 Monthly Distribution of $0.144 Per Share

NEW YORK, May 10, 2024 (GLOBE NEWSWIRE) — (NYSE: AIF) – Apollo Tactical Income Fund Inc. (the “Fund”) today announced the declaration of its distribution for the month of May 2024 of $0.144 per common share, payable on the date noted below. The following dates apply to the declared distribution: Ex-Date: May 22, 2024Record Date: May 23, 2024Payment Date: May 31, 2024Per Share Amount: $0.144 Apollo Contact Information: Product Literature877-864-4834 InvestorsElizabeth BesenInvestor Relations ManagerApollo Global Management, Inc.212-822-0625ebesen@apollo.com Forward-Looking StatementsThis press release may contain statements that are forward looking, as that term is defined by the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission in its rules, regulations and releases. These statements...

Continue reading

Apollo Senior Floating Rate Fund Inc. Declares May 2024 Monthly Distribution of $0.140 Per Share

NEW YORK, May 10, 2024 (GLOBE NEWSWIRE) — (NYSE: AFT) – Apollo Senior Floating Rate Fund Inc. (the “Fund”) today announced the declaration of its distribution for the month of May 2024 of $0.140 per common share, payable on the date noted below. The following dates apply to the declared distribution: Ex-Date: May 22, 2024Record Date: May 23, 2024Payment Date: May 31, 2024Per Share Amount: $0.140 Apollo Contact Information: Product Literature877-864-4834 InvestorsElizabeth BesenInvestor Relations ManagerApollo Global Management, Inc.212-822-0625ebesen@apollo.com Forward-Looking StatementsThis press release may contain statements that are forward looking, as that term is defined by the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission in its rules, regulations and releases. These...

Continue reading

FutureFuel Releases First Quarter 2024 Results

Reports Net Income of $4.3 Million or $0.10 per Diluted Share, and Adjusted EBITDA of $7.1 Million CLAYTON, Mo., May 10, 2024 (GLOBE NEWSWIRE) — FutureFuel Corp. (NYSE: FF) (“FutureFuel”), a manufacturer of custom and performance chemicals and biofuels, today announced financial results for the first quarter ended March 31, 2024. First quarter 2024 Financial Highlights (all comparisons are with the first quarter of 2023) Revenues were $58.3 million, a decrease of 21% or $15.9 million compared to $74.2 million. Net income was $4.3 million, or $0.10 per diluted share, down from $21.1 million, or $0.48 per diluted share. Adjusted EBITDA(1) was $7.1 million, down from $15.9 million. (1) A non-GAAP financial measure. See “Non-GAAP Financial Measures” for a description of the measure and a reconciliation to the applicable GAAP measure. “We...

Continue reading

Forward Reports Fiscal 2024 Second Quarter Results

HAUPPAUGE, N.Y., May 10, 2024 (GLOBE NEWSWIRE) — Forward Industries, Inc. (NASDAQ:FORD), a global design, sourcing and distribution group, today announced financial results for its second quarter ended March 31, 2024. Second Quarter Fiscal Year 2024 Financial Highlights    Revenues were $7.8 million, a decrease of 19.6% from $9.7 million for 2023. Gross margin increased to 20.5% compared to 19.8% for 2023. Loss from continuing operations was $0.5 million compared to $0.1 million in 2023 and net loss was $0.6 million compared to $0.9 million in 2023. Basic and diluted loss per share from continuing operations was $0.05 compared to $0.01 for 2023. Cash balance of $2.3 million at March 31, 2024 compared to $3.2 million at September 30, 2023. Terry Wise, Chief Executive Officer of Forward Industries, stated “The business continues...

Continue reading

Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates

JERUSALEM, May 10, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended March 31, 2024. “Entera is off to a strong start in 2024 thanks to the growth strategy we implemented in 2023, expanding our N-Tab™ therapeutic pipeline with potential first in class oral GLP-2, GLP-1/glucagon and PTH(1-34) peptide treatments for patients with GYN/endocrine, metabolic and gastrointestinal disorders. We thank our shareholders for their support. We are continuing on our mission to build Entera into a premier oral peptide therapeutic company and look forward to delivering key updates across all of our programs as this year progresses,” said Miranda...

Continue reading

Atrion Reports First Quarter 2024 Results

ALLEN, Texas, May 10, 2024 (GLOBE NEWSWIRE) — Atrion Corporation (NASDAQ: ATRI) today announced its results for the first quarter ended March 31, 2024. Revenues for the first quarter of 2024 totaled $47.3 million compared to $40.0 million for the same period in 2023. For the just ended quarter, operating income was $3.1 million, down $1.3 million from the comparable 2023 period, primarily due to a one-time inventory write-off, and net income was $2.8 million, down $0.7 million from the same period in 2023. First quarter 2024 diluted earnings per share were $1.59 compared to $1.98 for the first quarter of 2023. Commenting on the results for the first quarter of 2024 compared to the prior year period, David Battat, President and CEO, stated, “Revenues grew 18% and operating income was up 22%, excluding the one-time inventory write...

Continue reading

Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam

$126.3 Million In Total Gross Proceeds from Warrant Distribution. Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam. Over 735 Patients Have Completed a Phase 3 Trial of Simufilam. AUSTIN, Texas, May 10, 2024 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial results for first quarter ended March 31, 2024. Net income was $25.0 million compared to a net loss of $24.3 million for the same period in 2023. Net cash used in operations was $19.1 million during the first quarter of 2024. Cash use for operations for the first half of 2024 is still expected to be $35 to $45 million, driven primarily by expenses for our clinical program in Alzheimer’s disease. Current Updates on Phase 3 Clinical ProgramBackground...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.